|
||
|
Venture capital firms and funds in Europe 128 Venture Capital Group 3i Venture Capital Accuitive Medical Acer Venture Capital Act Venture Capital Ltd Adelaide Venture Capital Email ADS Ventures Boston Advantages Of Venture Capital Advent Venture Capital Agio Capital Alabama Venture Capital Alaska Venture Capital All Stages Venture Capital American Venture Capital Analysis Venture Capital Analyze Venture Capital Angel Capital Appraisal Venture Capital Arch Venture Capital Argentina Venture Capital Arizona Venture Capital Arkansas Venture Capital Arrowpath Venture Capital Assess Venture Capital Assessment Venture Capital Atlas Venture Capital ATV Venture Capital Aurora Fund Australia Venture Capital Austria Venture Capital Automotive Venture Capital AZ Venture Capital VCgate More Venture Capital Terms and Topics
-
Zogenix, Inc. raises $60 million in series A venture financing
August 29th, 2006 No comments
Zogenix, Inc., a privately held pharmaceutical company focused on medicines to treat CNS disorders and pain, recently announced that the company has raised $60 million in a Series A private financing. The financing was co-led by Clarus Ventures and Domain Associates, LLC. Additional investors included BA Venture Partners, Thomas, McNerney & Partners, and Life Science Angels, Inc. Proceeds from the financing have been used to fund the acquisition of the Intraject technology assets from Aradigm Corporation, a transaction also announced today by Aradigm. This financing will enable Zogenix to advance the clinical and commercial development of Intraject sumatriptan, the first needle-free, single-use, disposable, subcutaneous delivery system that will compete in the $2.5 billion triptan segment of the migraine market.
“We are very pleased to have the support of these leading venture capital investors whose investment validates the commercial potential of the Intraject technology platform,” said Roger L. Hawley , founder and Chief Executive Officer. “We will use the proceeds of this financing to accelerate completion of the commercial Intraject manufacturing process and support the global registration of Intraject sumatriptan. We expect to offer patients a unique, easy-to-use, needle-free delivery device coupled with the fastest acting and most efficacious acute migraine therapy available on the market, today.”
“We have recruited a world-class team with extensive knowledge of the Intraject technology,” added Stephen J. Farr, Ph.D., founder, President and Chief Operating Officer. “We see a number of exciting commercial product applications for Zogenix beyond Intraject sumatriptan and also plan to aggressively pursue partnerships for the development of additional applications of the Intraject technology.”
Concurrent with the financing, Zogenix named founder Cam L. Garner, as Chairman of its Board of Directors. Mr. Garner, the former Chairman and CEO of Dura Pharmaceuticals, brings an impressive track record of success in building specialty pharmaceutical companies. “Zogenix is built on a solid foundation of advanced technology and executive leadership with a clear strategic vision and directly relevant experience,” said Mr. Garner. “Coupled with a top-tier investor syndicate, the company is poised for market success.”
Mr. Garner is joined on the Zogenix Board by Directors Kurt C. Wheeler, Managing Director of Clarus Ventures; James C. Blair, Ph.D., Partner of Domain Associates; Louis C. Bock, Managing Director of BA Venture Partners; and Alex Zisson, Partner of Thomas, McNerney & Partners; and management team members Roger L. Hawley , Chief Executive Officer, and Stephen J. Farr, Ph.D., President and Chief Operating Officer.
“Zogenix is well-positioned to build an attractive CNS franchise and exploit the commercial potential of the Intraject technology,” said Kurt Wheeler of Clarus Ventures. “We look forward to working toward this goal with the Zogenix team and our co-investors.”
Leave a reply
Latest Headlines:
Friday August 31, 2012
Zscaler Secures $38 Million Investment Round
Wednesday November 30, 2011
Health Care Solutions companies Infinity Pharmaceutics, NanoVobronix and Selventa raise funds.
Monday November 21, 2011
Panda Power opens $420 Million Fund for Solar and Natural Gas Projects
Thursday November 17, 2011
Better Place raises $200 Million for Electric Cars in the Series C of Funding
Wednesday November 16, 2011
Accel Partners raise $100 Million Big Data Fund to Invest in Hadoop, NoSQL and other Companies
Tuesday November 15, 2011
Skimlinks raises $4.5 Million to help Bloggers Increase their Gains
Monday November 14, 2011
Standing Cloud raises $3 Million to help New Cloud Providers grow Faster
Thursday November 10, 2011
Zillow acquires Diverse Solutions for $7.8 to help Real Estate Agents increase their Visibility